Dados do Trabalho

Título

Comparison between PET/CT with 18F-PSMA-1007 and with 18F-FDG in Muscle-Invasive Bladder Urothelial Carcinoma

Introdução/Justificativa

Muscle-invasive bladder cancer (MIBC) presents high rates of metastasis and recurrence, making its monitoring challenging. PET/CT with 18F-FDG is relevant in evaluating this disease, although its urinary excretion makes the analysis of some cases difficult, even when diuretics are used. Prostate-specific membrane antigen (PSMA) is also expressed in neoangiogenesis of MIBC, making it a potential disease marker. In particular, the radiotracer 18F-PSMA-1007, unlike other analogs of this molecule, is predominantly excreted through the biliary tract, thereby facilitating the evaluation of the urinary tract.

Objetivos

The aim of this study was to compare PET/CT with 18F-FDG and with 18F-PSMA-1007 in evaluating MIBC.

Materiais e Métodos

Four male patients (ages 57-73 years) were prospectively studied, undergoing PET/CT 60 minutes after intravenous administration of 0.11 mCi/kg 18F-FDG and 5 and 90 minutes after intravenous injection of 18F-PSMA-1007. Additional late (2h) pelvic images were obtained with both tracers after intravenous furosemide injection. Images were analyzed by 2 experienced nuclear physicians and 1 radiologist. The maximum standardized uptake value (SUVmax) of each lesion was measured for both radiotracers.

Resultados

18F-PSMA-1007 uptake in bladder lesions and regional lymph nodes progressively increased between 5, 90 minutes and 2 hours. A total of 11 lesions were identified in the 4 patients using 18F-PSMA-1007 and 9 using 18F-FDG.
Two patients had undergone transurethral resection and had no active macroscopic lesions in the bladder. 18F-PSMA-1007 detected bladder lesions in the other 2 patients (SUVmax= 9.8 and 23.4), while FDG detected only 1 (SUVmax= 30.0), with the other lesion indistinguishable from radioactive urine, even after diuretic administration. Both tracers detected lymph node metastases in 3 patients (SUVmax= 4.1 to 15.8, and 9.5 to 18.3, respectively, for 18F-PSMA-1007 and 18F-FDG), and bone metastasis in 1 patient (SUVmax= 11.1 and 10.1 for 18F-PSMA-1007 and 18F-FDG, respectively). Two patients had pulmonary inflammatory/infectious processes that were FDG-avid but not 18F-PSMA-1007-avid.

Conclusão

PET/CTs with 18F-FDG and 18F-PSMA-1007 appear to have similar sensitivities for MIBC lesions. Due to lower uptake in inflammatory processes, 18F-PSMA-1007 appears to have higher specificity and, due to significantly lower urinary excretion than 18F-FDG, may be more favorable for evaluating the primary bladder lesion. The significant uptake of 18F-PSMA-1007 in MIBC lesions raises the possibility of theranostic approach in selected patients.

Palavras Chave

bladder cancer; PSMA PET; 18F-FDG PET/CT

Área

Medicina Nuclear